Verisante Technology, specializing in Cancer Imaging Technology has declared that it has obtained conformity notification to the European Medical Device Directive permitting Verisante Aura sales in Europe.
The out-break of skin cancers in Germany has increased over the years with melanoma responsible for 2,217 deaths every year urging the country to offer health insurance specifically for screening of skin cancer for people aged 35 and above.
With the increased frequency of several skin cancer types, progressive tools such as the Aura can be utilized by physicians to ascertain suspicious skin lesions sooner and will gradually gain significance in the heathcare sector. Verisante Aura was used to gather data on almost 1,000 lesions for a study at Vancouver General Hospital. Early detection can not only rescue the lives of melanoma patients but can also avoid increased healthcare costs. Melanoma , if detected and treated earlier, will increase the survival rate to 99 % with the treatment costing over $1,800 . During the final stages of the disease, the survival rate decreases to 15 %, while the treatment cost is as high as $170,000.
Verisante Aura has an extended application for the study of skin lesions that may be melanoma, basal cell carcinoma and/or squamous cell carcinoma. Aura is an optical system of non-invasive type, based on Raman spectroscopy and is developed as a tool to assist physicians in the biochemical evaluation of skin lesions suspected for skin cancer or a benign disorder. The Aura enables quick scanning of 20 to 40 skin lesions on persons at-risk enhancing comfort-levels and results obtained. The Company is all set to register Aura with Australia’s Therapeutic goods Administration.
Source: http://www.verisante.com/